Goeckerman therapy versus biologics in the treatment of psoriasis.
Alan
A
Menter
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003033:Coal Tar / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000191:economics; D006801:Humans; D000069285:Infliximab; D007641:Keratolytic Agents / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D014467:Ultraviolet Therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007641:Keratolytic Agents; D003033:Coal Tar; D000069285:Infliximab; D000068879:Adalimumab